A Phase 1, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD 0332334 In Subjects With Various Degrees Of Renal Function.

Trial Profile

A Phase 1, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD 0332334 In Subjects With Various Degrees Of Renal Function.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2010

At a glance

  • Drugs Imagabalin (Primary)
  • Indications Anxiety disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Mar 2009 Actual end date changed from Mar 2009 to Feb 2009 as reported by ClinicalTrials.gov.
    • 03 Mar 2009 Planned number of patients changed from 32 to 16 as reported by ClinicalTrials.gov.
    • 03 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top